Abiraterone Tablet
Product Images NDC 0143-9597

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Abiraterone (NDC 0143-9597). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Abiraterone Acetate Tablets 1)

Chemical structure of Abiraterone acetate, showing its steroidal backbone with specific methyl and hydrogen groups, an acetoxy group, and a pyridine ring attached, corresponding to the active ingredient in the Abiraterone 250 mg oral tablet by Hikma Pharmaceuticals USA Inc.*

FDA Label Image

Figure 1 (Abiraterone Acetate Tablets 2)

A line graph comparing the percentage survival over time in months between Abiraterone Acetate Tablet and placebo groups. The x-axis represents time to death in months, and the y-axis shows the percentage survival from 0 to 100%. Two survival curves are shown, one for the placebo (dashed line) and one for the Abiraterone Acetate Tablet (solid line), with patient numbers at risk listed below the x-axis for both groups at various time points.*

FDA Label Image

Figure 2 (Abiraterone Acetate Tablets 3)

A survival curve graph depicting the percentage of subjects without death over months from randomization comparing Abiraterone Acetate Tablets and Placebo. The x-axis shows months from 0 to 60, and the y-axis shows percent of subjects without death from 0 to 100. Two lines represent survival trends for the Abiraterone Acetate Tablets group and the Placebo group.*

FDA Label Image

Figure 3 (Abiraterone Acetate Tablets 4)

A Kaplan-Meier survival curve comparing Abiraterone Acetate Tablets and placebo groups. The y-axis shows the percentage of subjects without radiographic progression or death, and the x-axis shows months from randomization up to 18 months. The graph indicates greater progression-free survival for the Abiraterone group compared to placebo over time.*

FDA Label Image

Abiraterone-250mg-bl (Abiraterone Acetate Tablets 5)

A survival curve chart depicting percentage of subjects without death over months from randomization, comparing Abiraterone acetate with placebo. The chart includes a legend distinguishing the two groups and a table showing the number of subjects at risk at various time points.*

FDA Label Image

Abiraterone Acetate Tablets 6

Label for Abiraterone Acetate Tablets USP 250 mg, showing a package containing 120 tablets. The label includes a warning about handling by women who are or may be pregnant, storage instructions, and manufacturer details listing The Arab Pharmaceuticals Manufacturing Company and distribution by West-Ward Pharmaceuticals Corp. The label also displays a barcode and NDC 0143-9597.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.